BAUS 2023: The role of Urologists in the MDT: optimising clinical practice for non-metastatic castration-resistant prostate cancer (nmCRPC) patients
Description
Discover the highlights from the Bayer-sponsored symposium at BAUS 2023.
In conjunction with clinical and real-word data, Professor Noel Clarke shares his thoughts on the prostate cancer pathway and the importance of a multidisciplinary approach to treatment. He discusses the most recent developments in the treatment landscape and provides evidence for treatment of nmCRPC with Nubeqa▼ (darolutamide).
Mr Gianmarco Isgro leads a discussion on a patient case study, providing a deeper insight in the challenges faced when treating a patient across multiple clinical teams. He further discusses PSA monitoring and the need for a system within an MDT to earlier identify nmCRPC patients.
Interested in learning more? Watch the video below.
This symposium was organised and funded by Bayer plc.
Speakers
Professor Noel Clarke
Professor Noel Clarke is a Consultant Urological Surgeon at The Christie and Salford Royal Hospitals and Honorary Professor of Urological Oncology at The University of Manchester. His specialist expertise is in genito-urinary cancer and complex pelvic and retroperitoneal malignancy. He is the director of The Christie/UoM Genitourinary Cancer Research Group and the FASTMAN National Centre of Excellence for Prostate cancer research. He is also joint clinical lead for the National Prostate Cancer Audit and is closely involved with planning and coordination of multiple national/international cancer trials. Professor Clarke has co-authored 285 scientific publications and eight book chapters on urological cancer.
Mr Gianmarco Isgro
Mr Gianmarco Isgro is a Consultant Urological Surgeon in South Tees Hospitals NHS Foundation Trust with specialist interest in pelvic cancer surgery and renal surgery. He trained at the University of Bologna Medical School and the Freeman Hospital in Newcastle upon Tyne. He is actively involved in the refashioning of prostate cancer diagnostic and monitoring pathways across the region.
Abbreviations: BAUS, British Association of Urological Surgeons; MDT, multidisciplinary team; nmCRPC, non-metastatic castration-resistant prostate cancer.
Report Adverse Events
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search MHRA Yellow Card in Google Play or Apple App Store. Adverse events should also be reported to Bayer plc Tel: 01182 063 500, Fax: 01182 063 703, Email: pvuk@bayer.com.
If You Want to Report a Quality Complaint
Please report any quality complaint to Bayer Plc Email: qualitycomplaints@bayer.com For more information on how we process any personal data you share with us in relation to the above please see our Privacy Policy.
